BIOABSORBABLE SCAFFOLDS FOR PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH CORONARY ARTERY DISEASE: PROBLEMS AND FUTURE PERSPECTIVES
https://doi.org/10.17802/2306-1278-2019-8-3-72-84
Abstract
Highlights. Bioabsorbable vascular scaffolds for percutaneous coronary interventions in multivessel coronary
artery disease patients and concomitant type 2 diabetes mellitus may increase the effectiveness of endovascular treatment and improve the long-term prognosis.
The review article discusses recent data and evidences on the efficacy and safety of various stent generations for treating patients with coronary artery disease. The main complications commonly occurred following the implantation of drug-eluting stents in the long-term period are summarized, suggesting the rationale for the use of the next generation bioabsorbable vascular scaffolds in routine clinical practice. Bioabsorbable vascular scaffolds for endovascular treatment of patients with coronary artery disease show comparable efficacy compared with conventional drug-eluting stents. Particular attention is paid to the technical approaches of bioabsorbable vascular scaffold implantation, the use of intavascular imaging to control the implantation, as well as the timing of dual antiplatelet therapy in the postoperative period. The final term of the first-generation scaffold absorption, dual antiplatelet therapy, the effectiveness of bioabsorbable vascular scaffold-treated distal lesions and safety in patients with type 2 diabetes are highlighted. Future perspectives of using the next generation bioabsorbable vascular scaffolds that may improve the efficiency of percutaneous coronary interventions are presented.
About the Authors
Yu. S. Vorobeva
RUDN University
Russian Federation
Russian Federation
MD, PhD student at the Department of Hospital and Pediatric Surgery, Medical Institute
+7 (909) 151-26-89
6, Miklukho-Maklaya St., Moscow, Russian Federation, 117198
Z. K. Shugushev
RUDN University
Russian Federation
Russian Federation
MD, PhD, Chairman of the Department of Cardiovascular Surgery, Medical Institute
6, Miklukho-Maklaya St., Moscow, Russian Federation, 117198
A. G. Faibushevich
RUDN University
Russian Federation
Russian Federation
MD, PhD, Associate Professor, Chairman of the Department of Hospital and Pediatric Surgery, Medical Institute
6, Miklukho-Maklaya St., Moscow, Russian Federation, 117198
D. A. Maximkin
RUDN University
Russian Federation
Russian Federation
MD, PhD, Associate Professor at the Department of Hospital and Pediatric Surgery, Medical Institute
6, Miklukho-Maklaya St., Moscow, Russian Federation, 117198
References
1. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., Komori H, Tsuji T., Motohara S., Uehata H. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102(4): 399-404. DOI:10.1161/01.CIR.102.4.399.
2. Katagiri Y., Onuma Y., Asano T., Chichareon P., Collet C., Miyazaki Y., Piek J.J., Wykrzykowska J.J., Abizaid A., Ormiston J.A., Chevalier B., Serruys P.W. Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). EuroIntervention. – 2018;14(9): e1057-e1066. DOI: 10.4244/EIJ-D-18-00301.
3. Pereira G.T.R., La Manna A., Ichibori Y., Vergara-Martel A., Ramos Nascimento B., Samdani A.J., Capodanno D., D'Agosta G., Gravina G., Venuti G., Tamburino C., Attizzani G. Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry. Int J Cardiovasc Imaging. 2019. DOI: 10.1007/s10554-019-01636-3. [Epub ahead of print]
4. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O’Shaughnessy C., Mann J.T., Turco M., Caputo R, Bergin P., Greenberg J., Popma J.J. and Russell M.E. A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. N Engl. J. Med. 2004; 350 (3): 221–231.
5. Curcio A., Torella A. D., Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011;75(6): 1287-1296.
6. Grube E., Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug- eluting stent for coronary artery disease. Expert Rev. Med. Devices.2006; 3(6): 731-741. DOI: 10.1586/17434440.3.6.731.
7. Ormiston J.A., Serruys P.W., Regar E., Dudek D., Thuesen L., Webster M.W., Onuma Y., Garcia-Garcia H.M., McGreevy R., Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616): 899-907. DOI: 10.1016/S0140-6736(08)60415-8.
8. Papafaklis M.I., Bourantas C.V., Farooq V., Diletti R., Muramatsu T., Zhang Y., Fotiadis D.I., Onuma Y., Garcia H.M., Michalis L.K., Serruys P.W. In vivo assessment of the threedimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: Fusion of frequency domain optical coherence tomography and angiography. EuroIntervention. 2013;9(7): 890. DOI: 10.4244/EIJV9I7A147.
9. Katagiri Y., Onuma Y., Asano T., Chichareon P., Collet C., Miyazaki Y., Piek J.J., Wykrzykowska J.J., Abizaid A., Ormiston J.A., Chevalier B., Serruys P.W. Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). EuroIntervention. – 2018;14(9): e1057-e1066. DOI: 10.4244/EIJ-D-18-00301.
10. Frye R.L., August P., Brooks M.M., Hardison R.M., Kelsey S.F., MacGregor J.M., Orchard T.J., Chaitman B.R., Genuth S.M., Goldberg S.H., Hlatky M.A., Jones T.L., Molitch M.E., Nesto R.W., Sako E.Y., Sobel B.E. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360(24): 2503–2515. DOI: 10.1056/NEJMoa0805796.
11. Testa L., Biondi Zoccai G., Tomai F., Ribichini F., Indolfi C., Tamburino C., Bartorelli A., Petronio A.S., Bedogni F., De Carlo M. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS).Study design and rationale J Cardiovasc Med (Hagerstown). 2015;16(3): 253-258. DOI: 10.2459/JCM.0000000000000219.
12. Costa J.R.Jr., Abizaid A., Whitbourn R., Serruys P.W., Jepson N., Steinwender C., Stuteville M., Ediebah D., Sudhir K., Bartorelli A.L. Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial investigators. Catheter Cardiovasc Interv. 2019;93(1): E1-E7. DOI: 10.1002/ccd.27715.
13. Ormiston J.A., Serruys P.W., Regar E., Dudek D., Thuesen L., Webster M.W., Onuma Y., Garcia-Garcia H.M., McGreevy R., Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616): 899-907. DOI: 10.1016/S0140-6736(08)60415-8.
14. Kedhi E., Joesoef K.S., McFadden E., Wassing J., van Mieghem C., Goedhart D. and Smits P.C. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet (London, England). 2010; 375: 201–209. DOI: 10.1016/S0140-6736(09)62127-9.
15. Caixeta A., Campos C.M., Felix C., Chieffo A., Capranzano P., Kawamoto H., Tamburino C., Diletti R., de Ribamar Costa J. Jr., Onuma Y., van Geuns R.J., Bartorelli A.L., Colombo A., Tamburino C., Serruys P.W., Abizaid A. Predictors of Long-term Adverse Events After Absorb Bioresorbable Vascular Scaffold Implantation: A 1,933-Patient Pooled Analysis From International Registries. EuroIntervention. 2018: EIJ-D-16-00796. DOI: 10.4244/EIJ-D-16-00796 [Epub ahead of print].
16. Kimura T., Kozuma K., Tanabe K., Nakamura S., Yamane M., Muramatsu T., Saito S., Yajima J., Hagiwara N., Mitsudo K., Popma J.J., Serruys P.W., Onuma Y., Ying S., Cao S., Staehr P., Cheong W.F., Kusano H., Stone G.W. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur. Heart J. 2015;36(47): 3332-3342. DOI: 10.1093/eurheartj/ehv435.
17. Costa J.R.Jr., Abizaid A., Whitbourn R., Serruys P.W., Jepson N., Steinwender C., Stuteville M., Ediebah D., Sudhir K., Bartorelli A.L. Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial investigators. Catheter Cardiovasc Interv. 2019;93(1): E1-E7. DOI: 10.1002/ccd.27715.
18. Pereira G.T.R., La Manna A., Ichibori Y., Vergara-Martel A., Ramos Nascimento B., Samdani A.J., Capodanno D., D'Agosta G., Gravina G., Venuti G., Tamburino C., Attizzani G. Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry. Int J Cardiovasc Imaging. 2019. DOI: 10.1007/s10554-019-01636-3. [Epub ahead of print]
19. Berezovskaya G.A., Karpenko M.A., Petrishch N.N. Fibronektin – factor riska ili sashchiti posle intrakoronarnogo stentirovaniya. Regionarnoe krovoobrashchenie I mikrocirkulyaciya. 2013;12(4): 12 – 19 (in Russian). DOI: 10.24884/1682-6655-2013-12-4-12-19.
20. Gao R., Yang Y., Han Y., Huo Y., Chen J., Yu B., Su X., Li L., Kuo H.C., Ying S.W., Cheong W.F., Zhang Y., Su X., Xu B., Popma J.J., Stone G.W. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66(21): 2298-2309. DOI: 10.1016/j.jacc.2015.09.054
21. Kimura T., Kozuma K., Tanabe K., Nakamura S., Yamane M., Muramatsu T., Saito S., Yajima J., Hagiwara N., Mitsudo K., Popma J.J., Serruys P.W., Onuma Y., Ying S., Cao S., Staehr P., Cheong W.F., Kusano H., Stone G.W. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur. Heart J. 2015;36(47): 3332-3342. DOI: 10.1093/eurheartj/ehv435.
22. Diletti R., Serruys P.W., Farooq V., Sudhir K., Dorange C., Miquel-Hebert K., Veldhof S., Rapoza R., Onuma Y., Garcia-Garcia H.M., Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimuseluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164(5): 654-663. DOI: 10.1016/j.ahj.2012.08.010.
23. Veselovskaya N.G., Chumakova G.A., Suvorova A.A. Prognosirovanie riska restenosa koronarnih arteriy posle ih stentirovaniya u pacientov s ozhireniem. Serdce. 2013; 12(5): 305 – 310. (in Russian). DOI: 10.15829/1728-8800-2013-3-4-9.
24. Curcio A., Torella A. D., Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011;75(6): 1287-1296.
25. Gao R., Yang Y., Han Y., Huo Y., Chen J., Yu B., Su X., Li L., Kuo H.C., Ying S.W., Cheong W.F., Zhang Y., Su X., Xu B., Popma J.J., Stone G.W. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66(21): 2298-2309. DOI: 10.1016/j.jacc.2015.09.054
26. Arsenicheva O.V., Omel’yanenko M.G. Rol’ endotelial’noy disfunkcii I metabolicheskogo sindroma v rasvitii oslozhneniy intervencionnih vmeshatelstv u pacientov s ishemicheskoy bolesn’yu serdca. Kasanskiy medicinskiy zhurnal. 2013; 94(2): 5-9 (in Russian).
27. Katagiri Y., Onuma Y., Asano T., Chichareon P., Collet C., Miyazaki Y., Piek J.J., Wykrzykowska J.J., Abizaid A., Ormiston J.A., Chevalier B., Serruys P.W. Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). EuroIntervention. – 2018;14(9): e1057-e1066. DOI: 10.4244/EIJ-D-18-00301.
28. Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S.O., Popma J.J., McGreevy R., Zhang Z., Simonton C., Stone G.W. ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20): 1905-1915. DOI: 10.1056/NEJMoa1509038.
29. Diletti R., Serruys P.W., Farooq V., Sudhir K., Dorange C., Miquel-Hebert K., Veldhof S., Rapoza R., Onuma Y., Garcia-Garcia H.M., Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimuseluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164(5): 654-663. DOI: 10.1016/j.ahj.2012.08.010.
30. Colombo A., Moses J. W., Morice M. C., Ludwig J., Holmes D.R Jr., Spanos V., Louvard Y., Desmedt B., Di Mario C., Leon M.B. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004; 109(10): 1244-1249. DOI: 10.1161/01.CIR.0000118474.71662.E3.
31. Ormiston J.A., Serruys P.W., Regar E., Dudek D., Thuesen L., Webster M.W., Onuma Y., Garcia-Garcia H.M., McGreevy R., Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616): 899-907. DOI: 10.1016/S0140-6736(08)60415-8.
32. Gogas B.D., King S.B. 3rd, Samady H. Bioresorbable polymeric scaffolds for coronary revascularization: Lassons learnt from ABSORB III, ABSORB China, and ABSORB Japan. Glob Cardiol Sci Pract. 2015;2015(5): 62. DOI:10.5339/gcsp.2015.62.
33. Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S.O., Popma J.J., McGreevy R., Zhang Z., Simonton C., Stone G.W. ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20): 1905-1915. DOI: 10.1056/NEJMoa1509038.
34. Costa J.R.Jr., Abizaid A., Whitbourn R., Serruys P.W., Jepson N., Steinwender C., Stuteville M., Ediebah D., Sudhir K., Bartorelli A.L. Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial investigators. Catheter Cardiovasc Interv. 2019;93(1): E1-E7. DOI: 10.1002/ccd.27715.
35. Yarbekov R.R., Chegogidse N.A., SigaevI.Yu. Blizhayshaya I otdalennaya effektivnost’ chreskozhnogo koronarnogo vmeshatelstva u bolnih IBS s mnogososudistim porazheniem koronarnih arteriy I saharnim diabetom II tipa. Annali hirurgii. 2014;5:21 – 26 (in Russian)
36. Guagliumi G., Musumeci G., Sirbu V., Bezerra H.G., Suzuki N., Fiocca L., Matiashvili A., Lortkipanidze N., Trivisonno A., Valsecchi O., Biondi-Zoccai G., Costa M.A. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drugeluting stents. JACC Cardiovasc Interv. 2010;3(5): 531–539. DOI: 10.1016/j.jcin.2010.02.008.
37. Gogas B.D., King S.B. 3rd, Samady H. Bioresorbable polymeric scaffolds for coronary revascularization: Lassons learnt from ABSORB III, ABSORB China, and ABSORB Japan. Glob Cardiol Sci Pract. 2015;2015(5): 62. DOI:10.5339/gcsp.2015.62.
38. Kimura T., Kozuma K., Tanabe K., Nakamura S., Yamane M., Muramatsu T., Saito S., Yajima J., Hagiwara N., Mitsudo K., Popma J.J., Serruys P.W., Onuma Y., Ying S., Cao S., Staehr P., Cheong W.F., Kusano H., Stone G.W. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur. Heart J. 2015;36(47): 3332-3342. DOI: 10.1093/eurheartj/ehv435.
39. Floré V., Brown A.J., Giblett J.P., Liou K., Cranley J., Hoole S.P., West N.E.J. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a singlecentre experience. EuroIntervention. 2019;14(17): 1776-1783. DOI: 10.4244/EIJ-D-18-00262.
40. Alfonso F., Fernandez C. Second-generation drugeluting stents. Moving the field forward. J Am CollCardiol. 2011;58:26-29. DOI: 10.1016/j.jacc.2011.03.013.
41. Guagliumi G., Musumeci G., Sirbu V., Bezerra H.G., Suzuki N., Fiocca L., Matiashvili A., Lortkipanidze N., Trivisonno A., Valsecchi O., Biondi-Zoccai G., Costa M.A. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drugeluting stents. JACC Cardiovasc Interv. 2010;3(5): 531–539. DOI: 10.1016/j.jcin.2010.02.008.
42. Gao R., Yang Y., Han Y., Huo Y., Chen J., Yu B., Su X., Li L., Kuo H.C., Ying S.W., Cheong W.F., Zhang Y., Su X., Xu B., Popma J.J., Stone G.W. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66(21): 2298-2309. DOI: 10.1016/j.jacc.2015.09.054
43. Bezerra H.G., Costa M.A., Guagliumi G., Rollins A.M., Simon D.I. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv. 2009;2(11): 1035-1046. DOI: 10.1016/j.jcin.2009.06.019.
44. Floré V., Brown A.J., Giblett J.P., Liou K., Cranley J., Hoole S.P., West N.E.J. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a singlecentre experience. EuroIntervention. 2019;14(17): 1776-1783. DOI: 10.4244/EIJ-D-18-00262.
45. Serruys P., Ong A.T., Piek J.J., Neumann F.J., van der Giessen W.J., Wiemer M., Zeiher A., Grube E., Haase J., Thuesen L., Hamm C., Otto-Terlouw P.C. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent. EuroIntervention.2005; 1(1): 58-65.
46. Diletti R., Serruys P.W., Farooq V., Sudhir K., Dorange C., Miquel-Hebert K., Veldhof S., Rapoza R., Onuma Y., Garcia-Garcia H.M., Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimuseluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164(5): 654-663. DOI: 10.1016/j.ahj.2012.08.010.
47. Belch J.J., Dormandy J., Biasi G.M., Cairols M., Diehm C., Eikelboom B., Golledge J., Jawien A., Lepäntalo M., Norgren L., Hiatt W.R., Becquemin J.P., Bergqvist D., Clement D., Baumgartner I., Minar E., Stonebridge P., Vermassen F., Matyas L., Leizorovicz A. Results of the randomized, placebocontrolled clopidogrel and acetiylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR trial). J Vasc Surgery. 2010;52(4): 825-833. DOI: 10.1016/j.jvs.2010.04.027.
48. Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S.O., Popma J.J., McGreevy R., Zhang Z., Simonton C., Stone G.W. ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20): 1905-1915. DOI: 10.1056/NEJMoa1509038.
49. Bezerra H.G., Costa M.A., Guagliumi G., Rollins A.M., Simon D.I. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv. 2009;2(11): 1035-1046. DOI: 10.1016/j.jcin.2009.06.019.
50. Stone G.W., Midei M., Newman W., Sanz M., Hermiller J.B., Williams J., Farhat N., Mahaffey K.W., Cutlip D.E., Fitzgerald P.J., Sood P., Su X., Lansky A.J. SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008; 299(16): 1903 – 1913. DOI: 10.1001/jama.299.16.1903.
51. Bhatt D.L., Topol E.J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148(2):263-268.
52. Gogas B.D., King S.B. 3rd, Samady H. Bioresorbable polymeric scaffolds for coronary revascularization: Lassons learnt from ABSORB III, ABSORB China, and ABSORB Japan. Glob Cardiol Sci Pract. 2015;2015(5): 62. DOI:10.5339/gcsp.2015.62.
53. Belch J.J., Dormandy J., Biasi G.M., Cairols M., Diehm C., Eikelboom B., Golledge J., Jawien A., Lepäntalo M., Norgren L., Hiatt W.R., Becquemin J.P., Bergqvist D., Clement D., Baumgartner I., Minar E., Stonebridge P., Vermassen F., Matyas L., Leizorovicz A. Results of the randomized, placebocontrolled clopidogrel and acetiylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR trial). J Vasc Surgery. 2010;52(4): 825-833. DOI: 10.1016/j.jvs.2010.04.027.
54. Costa M.A., Yaqub M., Kereiakes D.J., Smith R.S., Yu X., Aji J., Cannon L.A., Wang J.C., Simonton C., Sood P., Sudhir K. 2 One-Year Outcomes after Implantation of XIENCE PRIME and XIENCE PRIME Long Lesion stents in Patients with Coronary Artery Disease: Primary Endpoint Results of the SPIRIT PRIME Multicenter Clinical Trial. J of the Am Coll of Cardiol. 2011;58(20)Supplement. DOI: 10.1016/j.jacc.2011.10.833.
55. Matteau A., Yeh R.W., Camenzind E., Steg P.G., Wijns W., Mills J., Gershlick A., de Belder M., Ducroucq G., Mauri L. Balancing Long-Term Riscks of Ishemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015;116(5): 686-693. DOI: 10.1016/j.amjcard.2015.05.036.
56. Yeh R.W., Silber S., Chen L., Chen S., Hiremath S., Neumann F.J., Qiao S., Saito S., Xu B., Yang Y., Mauri L.. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. 2017;10(3): 247-254. DOI: 10.1016/j.jcin.2016.11.004.
57. Guagliumi G., Musumeci G., Sirbu V., Bezerra H.G., Suzuki N., Fiocca L., Matiashvili A., Lortkipanidze N., Trivisonno A., Valsecchi O., Biondi-Zoccai G., Costa M.A. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drugeluting stents. JACC Cardiovasc Interv. 2010;3(5): 531–539. DOI: 10.1016/j.jcin.2010.02.008.
58. Bhatt D.L., Topol E.J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148(2):263-268.
59. Montalescott G. D., Brieger A.J., Dalby S., Park S.J., Mehrah R. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. J Am Coll Cardiol. 2015;66(7): 832-847. DOI: 10.1016/j.jacc.2015.05.053.
60. Tsuchiya Y, Lansky AJ, Costa R A., Mehran R., Pietras C., Shimada Y., Sonoda S., Cristea E., Negoita M., Dangas G.D., Moses J.W., Leon M.B., Fitzgerald P.J., Müller R., Störger H., Hauptmann K.E., Grube E. Effect of everolimus eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am. J. Cardiol. 2006;98: 464–469.
61. Matteau A., Yeh R.W., Camenzind E., Steg P.G., Wijns W., Mills J., Gershlick A., de Belder M., Ducroucq G., Mauri L. Balancing Long-Term Riscks of Ishemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015;116(5): 686-693. DOI: 10.1016/j.amjcard.2015.05.036.
62. Floré V., Brown A.J., Giblett J.P., Liou K., Cranley J., Hoole S.P., West N.E.J. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a singlecentre experience. EuroIntervention. 2019;14(17): 1776-1783. DOI: 10.4244/EIJ-D-18-00262.
63. Stuckey T.D., Kirtane A.J., Brodie B.R., Witzenbichler B., Litherland C., Weisz G., Rinaldi M.J., Neumann F.J., Metzger D.C., Henry T.D., Cox D.A., Duffy P.L., Mazzaferri E.L. Jr., Gurbel P.A., Mehran R., Généreux P., Ben-Yehuda O., Simonton C.A., Stone G.W. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv. 2017;10(16): 1607-1617. DOI: 10.1016/j.jcin.2017.05.059.
64. Bezerra H.G., Costa M.A., Guagliumi G., Rollins A.M., Simon D.I. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv. 2009;2(11): 1035-1046. DOI: 10.1016/j.jcin.2009.06.019.
65. Koh T.H. National Heart Centre, Singapore. BEACON Registry. An All-Comers Trial of the Biolimus A9-Eluting Stent. Presented at Angioplasty Summit-TCT Asia Pacific. 2006.
66. Montalescott G. D., Brieger A.J., Dalby S., Park S.J., Mehrah R. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. J Am Coll Cardiol. 2015;66(7): 832-847. DOI: 10.1016/j.jacc.2015.05.053.
67. Grube E., Hauptmann K.E., Buellesfeld L., Lim V., Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating (STEALTH). EuroIntervention. 2005;1(1):53-7.
68. Belch J.J., Dormandy J., Biasi G.M., Cairols M., Diehm C., Eikelboom B., Golledge J., Jawien A., Lepäntalo M., Norgren L., Hiatt W.R., Becquemin J.P., Bergqvist D., Clement D., Baumgartner I., Minar E., Stonebridge P., Vermassen F., Matyas L., Leizorovicz A. Results of the randomized, placebocontrolled clopidogrel and acetiylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR trial). J Vasc Surgery. 2010;52(4): 825-833. DOI: 10.1016/j.jvs.2010.04.027.
69. Stuckey T.D., Kirtane A.J., Brodie B.R., Witzenbichler B., Litherland C., Weisz G., Rinaldi M.J., Neumann F.J., Metzger D.C., Henry T.D., Cox D.A., Duffy P.L., Mazzaferri E.L. Jr., Gurbel P.A., Mehran R., Généreux P., Ben-Yehuda O., Simonton C.A., Stone G.W. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv. 2017;10(16): 1607-1617. DOI: 10.1016/j.jcin.2017.05.059.
70. Bhatt D.L., Topol E.J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148(2):263-268.
71. Serruys P.W., Farooq V., Kalesan B., de Vries T., Buszman P., Linke A., Ischinger T., Klauss V., Eberli F., Wijns W., Morice M.C., Di Mario C., Corti R., Antoni D., Sohn H.Y., Eerdmans P., Rademaker-Havinga T., van Es G.A., Meier B., Jüni P., Windecker S. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus Erodible Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6(8): 777-89. DOI: 10.1016/j.jcin.2013.04.011.
72. Matteau A., Yeh R.W., Camenzind E., Steg P.G., Wijns W., Mills J., Gershlick A., de Belder M., Ducroucq G., Mauri L. Balancing Long-Term Riscks of Ishemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015;116(5): 686-693. DOI: 10.1016/j.amjcard.2015.05.036.
73. Chevalier B., Wijns W., Silber S., Garcia E., Serra A., Paunovic D., Serruys P. Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial. EuroIntervention. 2015;11(5): 549-54. DOI: 10.4244/EIJY14M12_13.
74. Montalescott G. D., Brieger A.J., Dalby S., Park S.J., Mehrah R. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. J Am Coll Cardiol. 2015;66(7): 832-847. DOI: 10.1016/j.jacc.2015.05.053.
75. Fath-Ordoubadi F., Spaepen E., El-Omar M., Fraser D.G., Khan M.A., Neyses L., Danzi G.B., Roguin A., Paunovic D., Mamas M.A.. Outcomes in patients with acute and stable coronary syndromes; insights from the prospective NOBORI-2 study. PLoS One. 2014;9(2): e88577. DOI: 10.1371/journal.pone.0088577.
76. Stuckey T.D., Kirtane A.J., Brodie B.R., Witzenbichler B., Litherland C., Weisz G., Rinaldi M.J., Neumann F.J., Metzger D.C., Henry T.D., Cox D.A., Duffy P.L., Mazzaferri E.L. Jr., Gurbel P.A., Mehran R., Généreux P., Ben-Yehuda O., Simonton C.A., Stone G.W. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv. 2017;10(16): 1607-1617. DOI: 10.1016/j.jcin.2017.05.059.
77. Deb S., Wijeysundera H.C., Ko D.T., Tsubota H., Hill S., Fremes S.E. Coronary artery bypass graft surgery vs. percutaneous interventions in coronary revascularization: a systematic review. JAMA. 2013; 310(19): 2086-2095. DOI: 10.1001/jama.2013.281718
78. Neumann, F-J., Sousa-Uva M., Ahlsson A., Alfonso F. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2018; 00:1–96. DOI: 10.1093/eurheartj/ehy394.
79. Kapur A., Hall R.J., Malik I.S. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010; 55(5): 432-440. DOI: 10.1016/j.jacc.2009.10.014.
80. Luthra S., Leiva-Juárez M.M, Taggart D.P. Systematic Review of Therapies for Stable Coronary Artery Disease in Diabetic Patients. Ann Thorac Surg. 2015; 100(6): 2383-2397. DOI: 10.1016/j.athoracsur.2015.07.005.
81. Bundhun P.K., Wu Z.J., Chen M.H. Coronary artery bypass surgery compared with percutaneous coronary interventions in patients with insulin treated type 2 diabetes mellitus: a systematic review and meta-analysis of 6 randomized controlled trials. CardiovascDiabetol. 2016;15: 2. DOI: 10.1186/s12933-015-0323-z.
82. Holzmann, M.J., Rathsman B., Eliasson B., Kuhl J., Svensson A.M., Nyström T., Sartipy U. Long-term prognosis in patients with type 1 and 2 diabetes mellitus after coronary artery bypass grafting. J Am CollCardiol. 2015; 65(16): 1644-1652. DOI: 10.1016/j.jacc.2015.02.052.
83. Byrne R.A., Joner M., Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.Eur Heart J. 2015;36: 3320-3331. DOI: 10.1093/eurheartj/ehv511.
84. Sumin A.N., Besdenezhnih N.A., Besdenezhnih A.V. Faktori riska bolshih serdechno-sosudistih sobitiy v otdalennom periode koronarnogo shuntirovaniya u pacientov s ishemicheskoy bolesn’yu serdca pri nalichii saharnogo diabeta 2 tipa. Rossiyskiy kardiologicheskiy zhurnal. 2015; 6(122): 30-37 (in Russian). DOI: 10.15829/1560-4071-2015-6-30-37.
85. Besdenezhnih N.A., Sumin A.N. Revascularisaciyamiokarda u pacientov s ishemicheskoy bolesn’yu serdca pri nalichii saharnogo diabeta 2 tipa. Saharniydiabet. 2016; 19(6): 471-478 (in Russian). DOI: 10.14341/DM7922.
86. Ahn J., Rha S.W., Choi B., Park S., Choi W.G., Li H.U., Yu H., Byeon J., Moon S.K., Do S.T. Early Stage Vascular Response between Bare Metal Stent and Drug-free Bioresorbable Vascular Scaffold in Small-sized Peripheral Artery: A Preclinical Study in Porcine Femoral Arteries. Ann Vasc Surg. – 2019: S0890-5096(19)30396-6. DOI: 10.1016/j.avsg.2019.03.034.
87. Hommels T.M., Hermanides R.S., Rasoul S., Berta B., IJsselmuiden A.J.J., Jessurun G.A.J., Benit E., Pereira B., De Luca G., Kedhi E. The 1 year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study. Neth Heart J. 2019. DOI: 10.1007/s12471-019-1293-7 [Epub ahead of print].
88. Kraak R.P., Hassell M.E.C.J., Grundeken M.J., Koch K.T., Henriques J.P.S., Piek J.J., Jan Baan Jr., Vis M.M., Arkenbout E.K., Tijssen J.G.P., de Winter R.J., Wykrzykowska J.J., Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention. 2015;10(10): 1160-1168. DOI: 10.4244/EIJY14M08_08/
89. Rampat R., Williams T., Mayo T., Mengozzi M., Ghezzi P., Hildick-Smith D., Cockburn J. Association between inflammatory biomarkers and neointimal response following elective implantation of the ABSORB bioresorbable vascular scaffold. Coron Artery Dis. 2019; 30(3): 183-187. DOI: 10.1097/MCA.0000000000000699.
90. Dudek D., Onuma Y., Ormiston J.A., Thuesen L., Miquel-Hebert K., Serruys P.W. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: The ABSORB trial. EuroIntervention. 2012;7(9): 1060-1061. DOI: 10.4244/EIJV7I9A168.
91. Serruys P.W., Ormiston J., Onuma Y., Regar E., Gonzalo N., Garcia-Garcia H.M., Nieman K., Bruining N., Dorange C., Miquel-Hébert K., Veldhof S., Webster M., Thuesen L., Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): two-year outcomes and results from multiple imaging methods. Lancet. 2009; 373(9667): 897-910. DOI: 10.1016/S0140-6736(09)60325-1.
92. Serruys P.W, Garcia-Garcia H.M, Onuma Y. From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade. Eur Heart J. 2012;33 (1):16 25. DOI: 10.1093/eurheartj/ehr384.
93. Bourantas C.V., Papafaklis M.I., Garcia-Garcia H.M., Farooq V., Diletti R., Muramatsu T., et al. Shortand long-term implications of a bioresorbable vascular scaffold implantation on the local endothelial shear stress patterns. JACC Cardiovasc Interv. 2014;7(1):100– 1. DOI: 10.1016/j.jcin.2013.01.139.
94. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., Komori H, Tsuji T., Motohara S., Uehata H. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102(4): 399-404. DOI:10.1161/01.CIR.102.4.399.
95. Papafaklis M.I., Bourantas C.V., Farooq V., Diletti R., Muramatsu T., Zhang Y., Fotiadis D.I., Onuma Y., Garcia H.M., Michalis L.K., Serruys P.W. In vivo assessment of the threedimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: Fusion of frequency domain optical coherence tomography and angiography. EuroIntervention. 2013;9(7): 890. DOI: 10.4244/EIJV9I7A147.
96. Testa L., Biondi Zoccai G., Tomai F., Ribichini F., Indolfi C., Tamburino C., Bartorelli A., Petronio A.S., Bedogni F., De Carlo M. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS).Study design and rationale J Cardiovasc Med (Hagerstown). 2015;16(3): 253-258. DOI: 10.2459/JCM.0000000000000219.
97. Caixeta A., Campos C.M., Felix C., Chieffo A., Capranzano P., Kawamoto H., Tamburino C., Diletti R., de Ribamar Costa J. Jr., Onuma Y., van Geuns R.J., Bartorelli A.L., Colombo A., Tamburino C., Serruys P.W., Abizaid A. Predictors of Long-term Adverse Events After Absorb Bioresorbable Vascular Scaffold Implantation: A 1,933-Patient Pooled Analysis From International Registries. EuroIntervention. 2018: EIJ-D-16-00796. DOI: 10.4244/EIJ-D-16-00796 [Epub ahead of print].
98. Pereira G.T.R., La Manna A., Ichibori Y., Vergara-Martel A., Ramos Nascimento B., Samdani A.J., Capodanno D., D'Agosta G., Gravina G., Venuti G., Tamburino C., Attizzani G. Optical coherence tomography evaluation of the absorb bioresorbable scaffold performance for overlap versus non-overlap segments in patients with coronary chronic total occlusion: insight from the GHOST-CTO registry. Int J Cardiovasc Imaging. 2019. DOI: 10.1007/s10554-019-01636-3. [Epub ahead of print]
99. Curcio A., Torella A. D., Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011;75(6): 1287-1296.
100. Katagiri Y., Onuma Y., Asano T., Chichareon P., Collet C., Miyazaki Y., Piek J.J., Wykrzykowska J.J., Abizaid A., Ormiston J.A., Chevalier B., Serruys P.W. Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). EuroIntervention. – 2018;14(9): e1057-e1066. DOI: 10.4244/EIJ-D-18-00301.
101. Ormiston J.A., Serruys P.W., Regar E., Dudek D., Thuesen L., Webster M.W., Onuma Y., Garcia-Garcia H.M., McGreevy R., Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616): 899-907. DOI: 10.1016/S0140-6736(08)60415-8.
102. Costa J.R.Jr., Abizaid A., Whitbourn R., Serruys P.W., Jepson N., Steinwender C., Stuteville M., Ediebah D., Sudhir K., Bartorelli A.L. Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial investigators. Catheter Cardiovasc Interv. 2019;93(1): E1-E7. DOI: 10.1002/ccd.27715.
103. Kimura T., Kozuma K., Tanabe K., Nakamura S., Yamane M., Muramatsu T., Saito S., Yajima J., Hagiwara N., Mitsudo K., Popma J.J., Serruys P.W., Onuma Y., Ying S., Cao S., Staehr P., Cheong W.F., Kusano H., Stone G.W. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur. Heart J. 2015;36(47): 3332-3342. DOI: 10.1093/eurheartj/ehv435.
104. Gao R., Yang Y., Han Y., Huo Y., Chen J., Yu B., Su X., Li L., Kuo H.C., Ying S.W., Cheong W.F., Zhang Y., Su X., Xu B., Popma J.J., Stone G.W. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66(21): 2298-2309. DOI: 10.1016/j.jacc.2015.09.054
105. Diletti R., Serruys P.W., Farooq V., Sudhir K., Dorange C., Miquel-Hebert K., Veldhof S., Rapoza R., Onuma Y., Garcia-Garcia H.M., Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimuseluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164(5): 654-663. DOI: 10.1016/j.ahj.2012.08.010.
106. Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S.O., Popma J.J., McGreevy R., Zhang Z., Simonton C., Stone G.W. ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20): 1905-1915. DOI: 10.1056/NEJMoa1509038.
107. Gogas B.D., King S.B. 3rd, Samady H. Bioresorbable polymeric scaffolds for coronary revascularization: Lassons learnt from ABSORB III, ABSORB China, and ABSORB Japan. Glob Cardiol Sci Pract. 2015;2015(5): 62. DOI:10.5339/gcsp.2015.62.
108. Guagliumi G., Musumeci G., Sirbu V., Bezerra H.G., Suzuki N., Fiocca L., Matiashvili A., Lortkipanidze N., Trivisonno A., Valsecchi O., Biondi-Zoccai G., Costa M.A. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drugeluting stents. JACC Cardiovasc Interv. 2010;3(5): 531–539. DOI: 10.1016/j.jcin.2010.02.008.
109. Floré V., Brown A.J., Giblett J.P., Liou K., Cranley J., Hoole S.P., West N.E.J. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a singlecentre experience. EuroIntervention. 2019;14(17): 1776-1783. DOI: 10.4244/EIJ-D-18-00262.
110. Bezerra H.G., Costa M.A., Guagliumi G., Rollins A.M., Simon D.I. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv. 2009;2(11): 1035-1046. DOI: 10.1016/j.jcin.2009.06.019.
111. Belch J.J., Dormandy J., Biasi G.M., Cairols M., Diehm C., Eikelboom B., Golledge J., Jawien A., Lepäntalo M., Norgren L., Hiatt W.R., Becquemin J.P., Bergqvist D., Clement D., Baumgartner I., Minar E., Stonebridge P., Vermassen F., Matyas L., Leizorovicz A. Results of the randomized, placebocontrolled clopidogrel and acetiylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR trial). J Vasc Surgery. 2010;52(4): 825-833. DOI: 10.1016/j.jvs.2010.04.027.
112. Bhatt D.L., Topol E.J. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148(2):263-268.
113. Matteau A., Yeh R.W., Camenzind E., Steg P.G., Wijns W., Mills J., Gershlick A., de Belder M., Ducroucq G., Mauri L. Balancing Long-Term Riscks of Ishemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015;116(5): 686-693. DOI: 10.1016/j.amjcard.2015.05.036.
114. Montalescott G. D., Brieger A.J., Dalby S., Park S.J., Mehrah R. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. J Am Coll Cardiol. 2015;66(7): 832-847. DOI: 10.1016/j.jacc.2015.05.053.
115. Stuckey T.D., Kirtane A.J., Brodie B.R., Witzenbichler B., Litherland C., Weisz G., Rinaldi M.J., Neumann F.J., Metzger D.C., Henry T.D., Cox D.A., Duffy P.L., Mazzaferri E.L. Jr., Gurbel P.A., Mehran R., Généreux P., Ben-Yehuda O., Simonton C.A., Stone G.W. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv. 2017;10(16): 1607-1617. DOI: 10.1016/j.jcin.2017.05.059.
Review
For citations:
Vorobeva Yu.S., Shugushev Z.K., Faibushevich A.G., Maximkin D.A. BIOABSORBABLE SCAFFOLDS FOR PERCUTANEOUS CORONARY INTERVENTIONS IN PATIENTS WITH CORONARY ARTERY DISEASE: PROBLEMS AND FUTURE PERSPECTIVES. Complex Issues of Cardiovascular Diseases. 2019;8(3):72-84. (In Russ.) https://doi.org/10.17802/2306-1278-2019-8-3-72-84
Views:
1031
